Cancer Research

Papers
(The H4-Index of Cancer Research is 66. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Cancer Research in the Age of Big Data780
Abstract 6922: MDM2 inhibitor alrizomadlin induces ferroptosis through p53 dependent and independent pathways in TP53 wildtype NSCLC244
Abstract P84: Sorted cell populations with epigenetically silenced chromosomally dispersed reporter fluorophore gene as a test-system for the screening of non-genotoxic carcinogens218
Abstract IA002: Full circle: Return of value to ovarian cancer research participants, advocates, and survivors200
Abstract IA025: AI-powered discovery of biomarkers from histopathological images in ovarian cancer167
Abstract B058: VEGF inhibition enhances immune checkpoint blockade efficacy in ovarian cancer164
Abstract PR004: Phase 2 study of the PD-L1 inhibitor durvalumab and VEGFR inhibitor cediranib combination with and without PARP inhibitor olaparib in patients with recurrent ovarian cancer148
Abstract A051: Targeting notch signaling pathway with auranofin for endometrial cancer therapy145
Abstract A029: PARP-targeted alpha therapy for the treatment of PARP inhibitor resistant ovarian cancer139
Abstract B039: Application of unsupervised clustering to whole slide images of high-grade serous ovarian cancer predicts prognosis132
The Approaching Darwinian Era in Oncology127
Abstract P51: MCL-1 safeguards activated hair follicle stem cells to enable adult hair regeneration118
Abstract P30: Targeting B7-H3 Positive Solid Tumor Malignancies with Chimeric Antigen Receptor Epstein-Barr Virus Specific T Cells Armoured with An Engineered SerpinB9 Molecule for Improved Persistenc116
Abstract P56: Suppression of Breast Cancer Growth via Inhibition of c-Myc Expression by RUNX3114
Abstract A050: Truncated PPM1D cooperates with the PI3K pathway to drive Diffuse Midline Gliomas113
Abstract A002-PR011: Precision Diagnosis in High-Risk Pediatric Oncology through Integrated Whole Genome, Transcriptome, and Epigenome Profiling112
Abstract B031: Uncovering genetic and regulatory drivers of tumor-specific splicing in pediatric brain tumors112
Abstract 3358: Tertiary lymphoid structures (TLS) estimated by AI tools from digital H&E slides significantly enhance survival prediction in high-risk AJCC stages III/IV melanoma108
Abstract 4286: CHK1 as a novel therapeutic target for pleural mesothelioma107
Abstract 7035: Targeting Ewing sarcoma with a novel RBM39 degrader: DNA damage repair pathway effects101
Abstract 1585: KH815, a novel dual-payload TROP2-directed antibody-drug conjugate, shows potent antitumor efficacy in pre-clinical tumor model101
Abstract A021: CLK inhibition induces mis-splicing of SOX8 in alveolar rhabdomyosarcoma97
Abstract A027: Combined AKT and XPO1 Inhibition to Target Chimeric Transcription-Factor Driven Pediatric Sarcoma Pathogenesis97
Abstract IA003: Intersecting Developmental and Oncogenic Networks in ZFTA Fusion-Driven Brain Cancer94
Abstract 2651: Nuclear prothymosin α suppresses TGF-β-induced EMT by stabilizing smad7: implications for lung cancer progression and metastasis92
Abstract IA005: Fetal barriers to fusion protein-driven leukemogenesis92
Abstract 1701: Investigating trastuzumab-deruxtecan (DS-8201) resistance mechanisms using clinically relevant PDX models and combination strategies with anti-PD-1 antibody91
Abstract A068: A phase 2 study to investigate the efficacy and safety of acoustic cluster therapy with modified FOLFIRINOX in patients with locally advanced pancreatic cancer90
Abstract A117: Co-priming sonic hedgehog inhibitor sonidegib with plerixafor induces tumor microenvironment transformation that enhances fluorescent nanoparticle deposition in pancreatic tumor xenogra89
Abstract A035: KMT2D Loss Induces Enrichment of Plod2+ Fibroblasts in Pancreatic Cancer89
Neuroblastoma Differentiation: The Untapped Potential of Mitochondrial Uncouplers87
Abstract A027: HuR drives immune evasion, metastases and KRAS addiction in pancreatic ductal adenocarcinoma: implications for IO-based and KRAS inhibitor therapies87
Abstract 524: An integrative approach to unveiling biomarkers and therapeutic targets identifies novel treatment strategy for advanced prostate cancer86
Abstract 515: Repurposing nebivolol with dasatinib and CPI-613: A synergistic strategy to combat triple-negative breast cancer85
Abstract 115: S-adenosyl-methionine (SAM) synthesis protects ovarian cancer from chemotherapy induced DNA damage and contributes to cancer stem cell enrichment84
Abstract 691: Decentralized pan-cancer tumor profiling: a comprehensive performance evaluation of the MSK-IMPACT® Assay with SOPHiA DDMTM84
Abstract 817: A prospective, multi-center, phase IV study to evaluate safety and efficacy of Dr. Reddy’s bevacizumab (DRL_BZ) in patients with solid tumors84
Abstract 365: A dual mechanism of sensitivity to PLK4 inhibition by RP-1664 in neuroblastoma83
Abstract 244: Identification of proteins in the oncogenic FLT3-ITD signaling pathway using the APEX2 system83
Abstract 611: Actinobacteria from macroalgae as a source of new anti-lymphoma compounds83
Abstract 1108: Tissue and circulating DNA methylation profiling can recapitulate SCLC heterogeneity to enable identification of new biomarkers of clinical relevance82
Abstract 1066: OncoKBTM, MSK’s precision oncology knowledge base: 2024 updates82
Abstract 6063: ROSE12, a novel anti-CTLA-4 Switch antibody™ with FcγR affinity-enhanced Fc, evokes tumor-selective anti-tumor immune activation by extracellular ATP without systemic immune activation81
Abstract 1520: Obesity delays melanoma resistance to BRAF/MEKi inhibitors and alters melanoma metabolism81
Abstract 6096: Acquired CAR-T therapy resistance in a pre-clinical model of pediatric rhabdomyosarcoma minimal residual disease80
Abstract 5726: QLS1103, A highly potent and selective PARP7 inhibitor treating advanced solid tumors79
Abstract 6095: T-PureTM: A bispecific antibody cocktail for T cell isolation from human blood, enabling simple and affordable point-of-care CAR-T manufacturing79
Abstract 4822: Efficacy of 4-1BB-costimulated NKG2D CAR-T cells for synovial sarcoma in comparison with CAR-T cells targeting other antigens77
Abstract 5166: Increasing translatability of syngeneic mouse models of cancer through the application of human-validated, clinically relevant gene expression-based measurements of the tumor immune mic77
Abstract 7205: Targeting diverse pathways for the treatment of KRAS driven non-small cell lung cancer76
Abstract 7180: DNA methylation profiling of peripheral blood mononuclear cells from small-cell lung cancer patients treated with hypomethylating agent plus carboplatin74
Abstract 7326: ATG-201, a novel T-cell engager (TCE) effectively depletes B cells with reduced risk of CRS for the treatment of B cell malignancies and B cell related autoimmune diseases74
Abstract 7446: Stratification of cell therapies in solid tumor organoids using deep learning-derived imaging metrics73
Abstract 7388: Trends of diagnosis disclosure among individuals with plasma cell disorders73
Abstract 5365: Comparison of whole genome sequencing and target capture sequencing in lung cancer72
Abstract 6271: Interactions between CD8+ T cells and tumor cells decode tumor heterogeneity and provide treatment recommendations for colorectal cancer72
Abstract 7374: Body size and composition in relation to PI3K/AKT/mTOR signaling: insights into cancer risk and outcomes - a systematic review72
Abstract 7211: Proteolysis targeting chimeras (PROTACs) of oncogenic RET protein71
Abstract 4575: mRNA expression in paired saliva and blood samples from different cancer indices71
Abstract 7131: Integrative single-cell transcriptomic and epigenomic immune profiling reveals parallel insights into cancer research70
Abstract 4454: Cancer cell permeability induced by tumor treating fields (TTFields) improves chemotherapy uptake and requires cells to transverse through the G2/M phase under TTFields application70
Abstract 140: Profiling ECM biomarkers PRO-C3 and PRO-C5 in plasma from patients with esophagogastric cancer68
Abstract 3434: Evaluation of TCR-engineered T cells specific for KRAS G12V mutant peptide presented by HLA-A*02:0168
Abstract 6198: Framework for Pacific Island Cancer and Obesity Across the Lifespan: PICOLI, A multi-dataset analysis approach66
Abstract 2119: Targeting KIT in chromophobe renal cell carcinoma66
Abstract 1348: Investigation of sex disparity in hepatocarcinogenesis using a hydrodynamic tail vein injection mouse model66
Abstract 88: Ephrin receptor A4 is a regulator of metastatic colonization in triple negative breast cancer66
0.56061100959778